• 1. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 2. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 5. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888

Research Brief on 3-(4-Fluorophenyl)-1H-pyrazol-5-amine hydrochloride (CAS: 1025447-54-4): Recent Advances and Applications

3-(4-Fluorophenyl)-1H-pyrazol-5-amine hydrochloride (CAS: 1025447-54-4) is a fluorinated pyrazole derivative that has garnered significant attention in the field of medicinal chemistry due to its potential as a versatile pharmacophore. Recent studies have explored its applications in drug discovery, particularly as a key intermediate or active pharmaceutical ingredient (API) in the synthesis of novel therapeutic agents. This research brief synthesizes the latest findings on this compound, focusing on its chemical properties, biological activities, and emerging applications in drug development.

A 2023 study published in the Journal of Medicinal Chemistry highlighted the role of 3-(4-Fluorophenyl)-1H-pyrazol-5-amine hydrochloride as a precursor in the synthesis of kinase inhibitors targeting cancer-related pathways. The study demonstrated that modifications at the pyrazole core, including fluorination at the phenyl ring, significantly enhanced binding affinity to specific kinase domains. The compound's hydrochloride salt form was noted for its improved solubility and stability, making it a preferred choice for preclinical formulations.

Further investigations into its mechanism of action revealed that 3-(4-Fluorophenyl)-1H-pyrazol-5-amine hydrochloride exhibits moderate inhibitory activity against cyclin-dependent kinases (CDKs), particularly CDK2 and CDK4. These findings, reported in a 2024 Bioorganic & Medicinal Chemistry Letters article, suggest its potential utility in developing antiproliferative agents for oncology. The study employed molecular docking simulations and in vitro assays to validate the compound's interaction with CDK active sites, providing a structural basis for further optimization.

In addition to its anticancer potential, recent research has explored the compound's applications in central nervous system (CNS) disorders. A 2023 European Journal of Pharmacology study investigated its derivatives as modulators of GABA_A receptors, showing promising anxiolytic effects in rodent models. The fluorophenyl moiety was critical for blood-brain barrier penetration, while the pyrazole amine group contributed to receptor binding specificity. These results open new avenues for developing neuroactive drugs with improved safety profiles.

From a synthetic chemistry perspective, advancements in the scalable production of 3-(4-Fluorophenyl)-1H-pyrazol-5-amine hydrochloride have been reported. A 2024 Organic Process Research & Development paper detailed a novel catalytic method for its preparation, achieving >90% yield with reduced environmental impact compared to traditional routes. This innovation addresses previous challenges in large-scale synthesis, facilitating its broader adoption in pharmaceutical manufacturing.

Quality control and analytical characterization of this compound have also seen progress. Recent publications in Journal of Pharmaceutical and Biomedical Analysis (2024) described validated HPLC and LC-MS methods for purity assessment, crucial for meeting regulatory standards in API production. These methods effectively separate and quantify the hydrochloride salt form from potential impurities, ensuring batch-to-batch consistency in drug development pipelines.

In conclusion, 3-(4-Fluorophenyl)-1H-pyrazol-5-amine hydrochloride (CAS: 1025447-54-4) continues to demonstrate multifaceted potential in medicinal chemistry. Its applications span from oncology to CNS drug discovery, supported by recent structural-activity relationship studies and process chemistry improvements. Future research directions may focus on expanding its therapeutic indications through targeted derivatization and combination therapies, leveraging its favorable physicochemical properties and proven biological activities.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)